ES2355055T3 - Composiciones y procedimientos para el tratamiento de tumores. - Google Patents

Composiciones y procedimientos para el tratamiento de tumores. Download PDF

Info

Publication number
ES2355055T3
ES2355055T3 ES00950879T ES00950879T ES2355055T3 ES 2355055 T3 ES2355055 T3 ES 2355055T3 ES 00950879 T ES00950879 T ES 00950879T ES 00950879 T ES00950879 T ES 00950879T ES 2355055 T3 ES2355055 T3 ES 2355055T3
Authority
ES
Spain
Prior art keywords
adam8
antibody
cells
expression
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00950879T
Other languages
English (en)
Spanish (es)
Inventor
Sarah C. Bodary
Karen L. Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2355055T3 publication Critical patent/ES2355055T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES00950879T 1999-07-28 2000-07-27 Composiciones y procedimientos para el tratamiento de tumores. Expired - Lifetime ES2355055T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14621799P 1999-07-28 1999-07-28
US146217P 1999-07-28

Publications (1)

Publication Number Publication Date
ES2355055T3 true ES2355055T3 (es) 2011-03-22

Family

ID=22516336

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00950879T Expired - Lifetime ES2355055T3 (es) 1999-07-28 2000-07-27 Composiciones y procedimientos para el tratamiento de tumores.

Country Status (9)

Country Link
US (2) US7226596B2 (https=)
EP (1) EP1204682B1 (https=)
JP (3) JP2003508028A (https=)
AT (1) ATE488529T1 (https=)
AU (1) AU776600B2 (https=)
CA (1) CA2378182C (https=)
DE (1) DE60045247D1 (https=)
ES (1) ES2355055T3 (https=)
WO (1) WO2001009189A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE488529T1 (de) * 1999-07-28 2010-12-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren
CA2462133A1 (en) * 2002-02-20 2003-08-28 Kunitake Abe Novel polypeptide
CN1854313B (zh) * 2002-09-30 2010-10-20 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
WO2005011619A2 (en) * 2003-01-31 2005-02-10 Five Prime Therapeutics, Inc. Lung-expressed polypeptides
EP1730533A1 (en) * 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
ES2318575T3 (es) * 2004-11-10 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Interferon beta desamidado.
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
EP2290087A3 (en) * 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
EP2225563B1 (en) * 2007-11-27 2015-01-21 Janssen Diagnostics, LLC Automated enumeration and characterization of circulating melanoma cells in blood
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
EP2996721B1 (en) * 2013-05-13 2021-10-06 Tufts University Compositions for treatment of adam8-expressing cancer
TW201613621A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof
TW201613622A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for skincare and pharmaceutical composition and preparation method thereof
JP2018130113A (ja) * 2017-02-15 2018-08-23 国立大学法人 東京大学 慢性骨髄性白血病（ｃｍｌ）の検査方法及び検査用キット、チロシンキナーゼ阻害剤（ｔｋｉ）耐性ｃｍｌの単離方法、並びにｃｍｌにおけるｔｋｉ耐性の低減剤及びそのスクリーニング方法
EP3976655A4 (en) 2019-05-31 2023-07-05 Trustees of Tufts College Anti-adam8 antibodies and uses of the same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04187084A (ja) * 1990-11-22 1992-07-03 Otsuka Pharmaceut Co Ltd 単球表面に発現する抗原及び該抗原に対するモノクローナル抗体
PT822186E (pt) * 1994-01-20 2000-08-31 British Biotech Pharm L-tert-leucina-2-piridilamida
GB9608130D0 (en) 1996-04-19 1996-06-26 Univ Sheffield Adam proteins and uses thereof
WO1998031394A2 (en) 1997-01-22 1998-07-23 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment
GB9705521D0 (en) * 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
US5922566A (en) * 1997-05-13 1999-07-13 Incyte Pharmaceuticals, Inc. Tumor-associated antigen
WO1999064626A2 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
CA2702148C (en) * 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
ATE488529T1 (de) * 1999-07-28 2010-12-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren
NZ521437A (en) * 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
IL151872A0 (en) * 2000-03-24 2003-04-10 Micromet Ag mRNA AMPLIFICATION
US6458552B1 (en) * 2000-06-06 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. Metalloprotease peptide substrates and methods
US6818401B2 (en) * 2000-10-02 2004-11-16 Board Of Regents University Of Texas System Method of detection and interpretation of mutations through expression or function tests of haploid genes
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2002085285A2 (en) * 2001-04-18 2002-10-31 Wyeth Methods and reagents for regulating bone and cartilage formation
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
US20030148334A1 (en) * 2001-10-12 2003-08-07 Zairen Sun Differentially-expressed genes and polypeptides in angiogenesis
CA2477400A1 (en) * 2002-03-01 2003-09-12 Marc Rothenberg Treatment for asthma or allergies
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
JP2004041121A (ja) * 2002-07-12 2004-02-12 Hitachi Ltd アレルギー解析方法及びシステム
WO2004058052A2 (en) * 2002-12-20 2004-07-15 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US8088737B2 (en) * 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
US20050009067A1 (en) * 2003-05-19 2005-01-13 Craig Logsdon Expression profile of pancreatic cancer
WO2005026325A2 (en) * 2003-09-10 2005-03-24 Surromed, Inc, Bivalent targeting of cell surfaces

Also Published As

Publication number Publication date
JP5897300B2 (ja) 2016-03-30
EP1204682B1 (en) 2010-11-17
AU776600B2 (en) 2004-09-16
JP2003508028A (ja) 2003-03-04
US7226596B2 (en) 2007-06-05
CA2378182A1 (en) 2001-02-08
WO2001009189A3 (en) 2001-06-14
ATE488529T1 (de) 2010-12-15
AU6391300A (en) 2001-02-19
EP1204682A2 (en) 2002-05-15
WO2001009189A2 (en) 2001-02-08
JP2014144959A (ja) 2014-08-14
US20030113764A1 (en) 2003-06-19
US20080175842A1 (en) 2008-07-24
DE60045247D1 (de) 2010-12-30
CA2378182C (en) 2014-09-23
JP2012068254A (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
ES2296029T3 (es) Composiciones y procedimientos para el diagnostico de tumores.
US20080175842A1 (en) Compositions and methods for treatment
ES2331657T3 (es) Metodos para el diagnostico de tumores.
US20050176104A1 (en) Compositions and methods for the treatment of tumor
ES2323220T3 (es) Polipeptidos humanos stra6.
JP2009000114A (ja) 腫瘍治療のための組成物及び方法
JP2005531491A (ja) 癌の治療のための組成物と方法
WO2000015666A2 (en) Compositions and methods for the treatment of tumors
MXPA01006345A (es) Composiciones y metodos para el tratamiento de un tumor.